64 123

Cited 0 times in

Clinical features and outcomes of hypocellular acute myeloid leukemia in adults: A Korean AML registry data

 Ik-Chan Song  ;  Deog-Yeon Jo  ;  Hyeoung-Joon Kim  ;  Yoo-Hong Min  ;  Dae Sik Hong  ;  Won-Sik Lee  ;  Ho-Jin Shin  ;  Je-Hwan Lee  ;  Jinny Park  ;  Hee-Je Kim 
 MEDICINE, Vol.100(1) : e24185, 2021-01 
Journal Title
Issue Date
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Leukemia, Myeloid, Acute / classification* ; Leukemia, Myeloid, Acute / epidemiology ; Leukemia, Myeloid, Acute / mortality* ; Male ; Middle Aged ; Nucleophosmin ; Prognosis ; Registries / statistics & numerical data ; Remission Induction ; Republic of Korea / epidemiology ; Retrospective Studies
The hypocellular variant of acute myeloid leukemia (AML) is defined as bone marrow cellularity of <20% in a biopsy specimen at presentation. We performed a retrospective analysis of the clinical features and survival outcomes of hypocellular AML in a Korean population. We reviewed the medical records of all patients diagnosed with AML at nine hospitals participating in the Korean AML registry from 2006 to 2012. Overall survival (OS) and event-free survival (EFS) rates were calculated from the time of diagnosis until death or an event, respectively. In total, 2110 patients were enrolled and 102 (4.8%) were identified as having hypocellular AML. Patients with hypocellular AML were older than those with non-hypocellular AML (median age: 59 vs 49 years; P < .001) and presented with leukopenia more frequently (mean white blood cell count: 5810/μL vs 40549/μL; P < .001). There was no difference between patients with and without hypocellular AML in terms of the presence of antecedent hematologic disorders (5.9% vs 5.3%; P = .809). FLT3-ITD and NPM1 mutations were less common in hypocellular than non-hypocellular AML (FLT3-ITD mutations: 1.2% vs 14.3%, P < .001; NPM1 mutations: 0% vs 9.5%, P = .019). No differences were seen between the hypocellular and non-hypocellular AML groups in the complete remission rate (53.9% vs 61.3%, P = .139) or early death rate (defined as any death before 8 weeks; 14.7% vs 13.0%, P = .629). The OS and EFS did not differ between the hypocellular and non-hypocellular AML groups (median OS: 16 vs 23 months, P = .169; median EFS: 6 vs 9 months, P = .215). Hypocellular AML is more frequently observed in older-aged patients and have fewer FLT3-ITD and NPM1 mutation, but the clinical outcomes of hypocellular AML do not differ from those of non-hypocellular AML.
Files in This Item:
T202125987.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Min, Yoo Hong(민유홍) ORCID logo https://orcid.org/0000-0001-8542-9583
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.